Achilles Therapeutics PLC ACHL
We take great care to ensure that the data presented and summarized in this overview for Achilles Therapeutics plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACHL
View all-
Bml Capital Management, LLC Zionsville, IN3.8MShares$5.63 Million0.0% of portfolio
-
Xtx Topco LTD London, X038.9KShares$57,6060.0% of portfolio
-
Brave Asset Management Inc10KShares$14,8000.0% of portfolio
-
Rhumbline Advisers Boston, MA4.48KShares$6,6300.0% of portfolio
-
Endurance Wealth Management, Inc.2KShares$2,9600.0% of portfolio
-
Gamma Investing LLC Foster City, CA806Shares$1,1920.0% of portfolio
-
Sbi Securities Co., Ltd. Tokyo, M0196Shares$2900.0% of portfolio
Latest Institutional Activity in ACHL
Top Purchases
Top Sells
About ACHL
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Insider Transactions at ACHL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|